Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.42 |
| ▸ | NPY1R | P25929 | 6/20 | 0.42 |
| ▸ | NPY2R | P49146 | 4/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | FNTA | P49354 | 8/20 | 0.38 |
| ▸ | FNTB | P49356 | 8/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480363 | 0.96 | NPY4R (0.40) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30390767 | 0.95 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30272461 | 0.94 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29754666 | 0.93 | NPY4R (0.40) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30390440 | 0.93 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30790301 | 0.93 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL30391081 | 0.93 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31453814 | 0.93 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29452752 | 0.93 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RAPLNR | |
| SCHEMBL1071152 | 0.92 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12251395-B2 | RNAS for complement inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240285783-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240285725-A1 | DOSING REGIMENS | SIXTH STREET LENDING PARTNERS | 2024-08-29 | — | — | US | disclosed |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240218018-A1 | Compstatin Analogs with Increased Solubility and Improved Pharmacokinetic Properties | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2023-09-28 | — | — | US | disclosed |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | APELLIS PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230190578-A1 | REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGS | CureVac SE (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2023-03-23 | — | — | US | disclosed |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3996744-A1 | VIRAL VECTOR THERAPY | Apellis Pharmaceuticals, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | NPY4R 3166/4885NPY1R 2474/4885NPY2R 2313/4885 |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | NPY4R 3166/4885NPY1R 2474/4885NPY2R 2313/4885 |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | NPY4R 3166/4885NPY1R 2474/4885NPY2R 2313/4885 |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | C3AR1, C5, CFH | NPY4R 1861/4885NPY1R 2800/4885NPY2R 2805/4885 |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | C9, C3AR1, SERPINC1 | NPY4R 3320/4885NPY1R 3275/4885NPY2R 3717/4885 |
| US-20240285725-A1 | DOSING REGIMENS | C3AR1, C1QBP, C9 | NPY4R 1317/4885NPY1R 1058/4885NPY2R 1825/4885 |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | NPY4R 1745/4885NPY1R 1523/4885NPY2R 2313/4885 |
| US-12251395-B2 | RNAS for complement inhibition | SNRPE, RNASE1, SNRPF | NPY4R 4780/4885NPY1R 4644/4885NPY2R 4712/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | NPY4R 1340/4885NPY1R 1117/4885NPY2R 1518/4885 |
| US-11338013-B2 | Combination therapy for C3 inhibition | C3AR1, C5, CFH | NPY4R 1861/4885NPY1R 2800/4885NPY2R 2805/4885 |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SNRPE, RNASE1, SNRPF | NPY4R 4780/4885NPY1R 4644/4885NPY2R 4712/4885 |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | NPY4R 3166/4885NPY1R 2474/4885NPY2R 2313/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | NPY4R 2820/4885NPY1R 3104/4885NPY2R 3993/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | NPY4R 3281/4885NPY1R 3248/4885NPY2R 3688/4885 |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | CFH, CFB, HAVCR2 | NPY4R 4428/4885NPY1R 4634/4885NPY2R 4707/4885 |
| US-20240285783-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | NPY4R 1598/4885NPY1R 1201/4885NPY2R 2157/4885 |
| US-11712460-B2 | Methods of treating chronic disorders with complement inhibitors | C5, C3AR1, C1QBP | NPY4R 1080/4885NPY1R 1140/4885NPY2R 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.